Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging

Antimicrobial peptides (AMPs) are a heterogeneous class of compounds found in a variety of organisms including humans and, so far, hundreds of these structures have been isolated and characterised. They can be described as natural microbicide, selectively cytotoxic to bacteria, whilst showing minimal cytotoxicity towards the mammalian cells of the host organism. They act by their relatively strong electrostatic attraction to the negatively charged bacterial cells and a relatively weak interaction to the eukaryote host cells. The ability of these peptides to accumulate at sites of infection combined with the minimal host's cytotoxicity motivated for this review to highlight the role and the usefulness of AMPs for PET with emphasis on their mechanism of action and the different interactions with the bacterial cell. These details are key information for their selective properties. We also describe the strategy, design, and utilization of these peptides as potential radiopharmaceuticals as their combination with nuclear medicine modalities such as SPECT or PET would allow noninvasive whole-body examination for detection of occult infection causing, for example, fever of unknown origin.

[1]  Alessandro Tossi,et al.  Amphipathic, α‐helical antimicrobial peptides , 2000 .

[2]  Dong-Kuk Lee,et al.  Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. , 2003, Biochemistry.

[3]  D. Wareham,et al.  99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  E. Pauwels,et al.  99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Y. Shai,et al.  Mode of action of membrane active antimicrobial peptides. , 2002, Biopolymers.

[6]  R. Hancock,et al.  Interaction of Cationic Antimicrobial Peptides with Model Membranes* , 2001, The Journal of Biological Chemistry.

[7]  M. Dathe,et al.  Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. , 1999, Biochimica et biophysica acta.

[8]  F. Gemmel,et al.  Clinical trial of specific imaging of infections , 2010, Nuclear medicine communications.

[9]  T. Ganz Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.

[10]  E. Pauwels,et al.  Radiopharmaceuticals: new antimicrobial agents. , 2003, Trends in biotechnology.

[11]  C. Palestro Radionuclide Imaging of Infection: In Search of the Grail , 2009, Journal of Nuclear Medicine.

[12]  L. Dijkshoorn,et al.  The Synthetic N-Terminal Peptide of Human Lactoferrin, hLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii , 2004, Antimicrobial Agents and Chemotherapy.

[13]  K. Matsuzaki,et al.  Polar Angle as a Determinant of Amphipathic α-Helix-Lipid Interactions: A Model Peptide Study , 2000 .

[14]  H. Maecke,et al.  68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. , 2008, Contrast media & molecular imaging.

[15]  O. Kuipers,et al.  Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. , 1999, Science.

[16]  Katsumi Matsuzaki,et al.  Control of cell selectivity of antimicrobial peptides. , 2009, Biochimica et biophysica acta.

[17]  S. Blondelle,et al.  Lipid-induced conformation and lipid-binding properties of cytolytic and antimicrobial peptides: determination and biological specificity. , 1999, Biochimica et biophysica acta.

[18]  W. Marsden I and J , 2012 .

[19]  T. Govender,et al.  Preclinical Evaluation of 68Ga-Labeled 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid-Ubiquicidin as a Radioligand for PET Infection Imaging , 2014, The Journal of Nuclear Medicine.

[20]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[21]  G. Ferro-Flores,et al.  Biokinetics of (99m)Tc-UBI 29-41 in humans. , 2004, Nuclear medicine and biology.

[22]  R I Lehrer,et al.  Crystallization of antimicrobial pores in membranes: magainin and protegrin. , 2000, Biophysical journal.

[23]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[24]  G. Ferro-Flores,et al.  Lys and Arg in UBI: a specific site for a stable Tc-99m complex? , 2003, Nuclear medicine and biology.

[25]  E. Pauwels,et al.  99mTc-Labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Michael Bienert,et al.  Optimization of the antimicrobial activity of magainin peptides by modification of charge , 2001, FEBS letters.

[27]  I. Nabipour,et al.  Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging , 2011, Nuclear medicine communications.

[28]  A. Signore,et al.  Receptor targeting agents for imaging inflammation/infection: where are we now? , 2006, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[29]  P. Nibbering,et al.  Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages , 1999, Journal of leukocyte biology.

[30]  Eduardo Guaní-Guerra,et al.  Antimicrobial peptides: general overview and clinical implications in human health and disease. , 2010, Clinical immunology.

[31]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[32]  Huey W. Huang,et al.  Action of antimicrobial peptides: two-state model. , 2000, Biochemistry.

[33]  B D Sykes,et al.  Dissociation of Antimicrobial and Hemolytic Activities in Cyclic Peptide Diastereomers by Systematic Alterations in Amphipathicity* , 1999, The Journal of Biological Chemistry.

[34]  B. Neumeister,et al.  Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. , 2002, The Journal of infectious diseases.

[35]  M. Pomper,et al.  The evolution of imaging in cancer: current state and future challenges. , 2011, Seminars in oncology.

[36]  A. Tossi,et al.  Amphipathic alpha helical antimicrobial peptides. , 2001, European journal of biochemistry.

[37]  A. Ianoul,et al.  Imaging the membrane lytic activity of bioactive peptide latarcin 2a. , 2012, Biochimica et biophysica acta.

[38]  T. Govender,et al.  Peptide synthesis, characterization and ⁶⁸Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT. , 2014, Nuclear medicine and biology.

[39]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[40]  M. Assadi,et al.  Role of 99mTc-ubiquicidin 29–41 scintigraphy to monitor antibiotic therapy in patients with orthopedic infection: a preliminary study , 2011, Nuclear medicine communications.

[41]  H. Jörnvall,et al.  The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. , 2000, Blood.

[42]  H. Vogel,et al.  Diversity of antimicrobial peptides and their mechanisms of action. , 1999, Biochimica et biophysica acta.

[43]  A. Tossi,et al.  Alpha-helical antimicrobial peptides--using a sequence template to guide structure-activity relationship studies. , 2006, Biochimica et biophysica acta.

[44]  L. Yang,et al.  Barrel-stave model or toroidal model? A case study on melittin pores. , 2001, Biophysical journal.

[45]  R. Nagaraj,et al.  Interaction of antimicrobial peptides with biological and model membranes: structural and charge requirements for activity. , 1999, Biochimica et biophysica acta.

[46]  Michael R. Yeaman,et al.  Mechanisms of Antimicrobial Peptide Action and Resistance , 2003, Pharmacological Reviews.

[47]  W. Oyen,et al.  Radiopharmaceuticals for scintigraphic imaging of infection and inflammation , 2001, Inflammation Research.

[48]  W. Oyen,et al.  Imaging infection/inflammation in the new millennium , 2001, European Journal of Nuclear Medicine.

[49]  S. Vallabhajosula,et al.  Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications. , 2009, Seminars in nuclear medicine.

[50]  K. Matsuzaki Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. , 1999, Biochimica et biophysica acta.

[51]  C. Brouwer,et al.  Discovery and development of a synthetic peptide derived from lactoferrin for clinical use , 2011, Peptides.

[52]  E. Krause,et al.  Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. , 1997, Biochemistry.

[53]  Andreas Peschel,et al.  How do bacteria resist human antimicrobial peptides? , 2002, Trends in microbiology.

[54]  M. Assadi,et al.  Technetium-99m-ubiquicidin scintigraphy in the detection of infective endocarditis. , 2014, Hellenic journal of nuclear medicine.

[55]  I. Nabipour,et al.  Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging , 2011, Nuclear medicine communications.

[56]  D. Rijkers,et al.  Membrane-Spanning Peptides Induce Phospholipid Flop: A Model for Phospholipid Translocation across the Inner Membrane of E. coli , 2001 .

[57]  D. Wareham,et al.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations , 2000, European Journal of Nuclear Medicine.

[58]  M. Imran,et al.  Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human infection-imaging agent: clinical trial. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  K. Brogden Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? , 2005, Nature Reviews Microbiology.

[60]  S. K. Shukla,et al.  Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. , 2010, Biochimie.

[61]  W. Maloy,et al.  Structure–activity studies on magainins and other host defense peptides , 1995, Biopolymers.

[62]  Jonathan Cohen,et al.  A prospective study of fever in the intensive care unit , 1999, Intensive Care Medicine.

[63]  A. Gholamrezanezhad,et al.  99mtc-Ubiquicidin [29–41], a Promising Radiopharmaceutical to Differentiate Orthopedic Implant Infections from Sterile Inflammation , 2013, Iranian journal of pharmaceutical research : IJPR.

[64]  A. Peschel,et al.  Key Role of Teichoic Acid Net Charge inStaphylococcus aureus Colonization of Artificial Surfaces , 2001, Infection and Immunity.

[65]  J. Bading,et al.  Integrin αβ3-Targeted Imaging of Lung Cancer , 2005 .

[66]  E. Pauwels,et al.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations , 2000, European Journal of Nuclear Medicine.

[67]  M. Yeaman,et al.  Multidimensional signatures in antimicrobial peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Sadeghi,et al.  (99m)Tc-labeled ubiquicidin scintigraphy: a promising method in hip prosthesis infection diagnosis. , 2012, Nuklearmedizin. Nuclear medicine.

[69]  J. Meller,et al.  The role of nuclear medicine in infection and inflammation. , 2001, The Lancet. Infectious diseases.

[70]  E. Pauwels,et al.  Peptide radiopharmaceuticals in nuclear medicine , 1999, European Journal of Nuclear Medicine.

[71]  C. Brouwer,et al.  The pharmacology of radiolabeled cationic antimicrobial peptides. , 2008, Journal of pharmaceutical sciences.

[72]  W. Burchert,et al.  Comparison of 99mTc- and 18F-Ubiquicidin Autoradiography to Anti–Staphylococcus aureus Immunofluorescence in Rat Muscle Abscesses , 2008, Journal of Nuclear Medicine.

[73]  J. M. Sanderson,et al.  Peptide-lipid interactions: insights and perspectives. , 2005, Organic & biomolecular chemistry.

[74]  Subhani M Okarvi,et al.  Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases , 2004, Medicinal research reviews.

[75]  A. Alavi,et al.  Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. , 2009, Seminars in nuclear medicine.

[76]  Oscar P. Kuipers,et al.  Specific Binding of Nisin to the Peptidoglycan Precursor Lipid II Combines Pore Formation and Inhibition of Cell Wall Biosynthesis for Potent Antibiotic Activity* , 2001, The Journal of Biological Chemistry.

[77]  G. Ferro-Flores,et al.  In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. , 2003, Nuclear medicine and biology.